Everest Medicines (HKG: 1952) announced that on 14 May 2026, based on strong confidence in the company’s future prospects and long-term development, Mr. Wei...
- Demonstrating a Favorable Safety Profile, Robust Immunogenicity, and Promising Preliminary Efficacy
Apr 20, Everest Medicines Limited announced that the first-in-human (FIH) clinical trial data...
Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited (CORXEL). Under the agreement, the...
March 9, Everest Medicines (HKG: 1952) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the...
Everest Medicines shareholders passed all proposed resolutions at an extraordinary general meeting (the EGM) held virtually on February 24, 2026, the company said in...
Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with...
Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...
